Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Clinician,Ipilimumab and nivolumab,"Renal cell carcinoma, metastatic, clear-cell, 1st line, intermediate and poor prognosis",Ipilimumab and nivolumab (Yervoy and Opdivo),Hospital,Oncology Agents and Immunosuppressants
